Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 66

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 66
---
 Debt SPA, the Company agreed to grant the investor the right to purchase up to an additional $ 10.0million worth of convertible preferred shares beginning six months after the closing and continuing for as long as the investor owns preferred shares. Any additional preferred shares issued upon the investor’s right being exercised will be identical to the initial preferred shares except the conversion price will be based on the average daily closing sale price of common shares for the five trading days prior to the investor giving notice of its intent to exercise its rights. Additionally, pursuant to the Debt SPA, the Company agreed to grant the investor the right to participate in up to fifty percent ( 50%) of future offerings of the Company’s securities for one year following the closing. In addition, the Company agreed not to enter into an equity line of credit or similar agreement, without the consent of the majority of the holders of the preferred shares. In October 2024, the Company amended and restated its articles of association to designate 806,452of preferred shares with a par value of 0.03CHF ($ .03689USD) (the “Preferred Shares”) in connection with the execution of a securities purchase agreement. The Preferred Shares have the following rights, preferences and privileges: •Accrue dividends at an annual rate of eight percent ( 8%) of the stated value of the preferred shares from the date of issuance; •Stated value and initial conversion price of $ 4.96, subject to adjustment, for share splits, dividends and the subsequent sale or issuance of equity and equity -linkedinstruments with an effective price per share that is lower than the initial conversion price (“Down Round Provision”); and •Have no voting rights. Upon any liquidation, dissolution or winding up of the Company, the preferred shareholders will be entitled to receive an amount equal to the stated value of any Preferred Shares held at the time of such an event prior to any holders of common shares. Annex A-14 NLS PHARMACEUTICS LTD.
NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS On November 13, 2024, as disclosed in the Company’s Report on Form 6 -Kfiled with the SEC on November 15, 2024, the Company filed amended and restated articles of association with the commercial registry of the Canton of Zurich, Switzerland, to reflect the following: •Capital increase of CHF 29,887.20through the issuance of 37,359registered common shares with a nominal